ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
How to get to Centro de distribución TEVA PHARMACEUTICALS MEXICO in Tepotzotlán by Bus?
Teva Announces New Organization Structure and Leadership Changes | Business Wire